Last reviewed · How we verify

NCT05881954

Outcomes of Natives and Graft-related Femoral Reconstruction With Tubulized Pericardial Patchs

Status unknown Last updated 31 May 2023
What this trial tests

trial testing Groin infection in Vascular Complications in 20 participants. Status unknown.

Timeline
1 January 2020
Primary endpoint
10 January 2020
1 September 2023

Quick facts

Lead sponsorUniversity Paul Sabatier of Toulouse
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date1 January 2020
Primary completion10 January 2020
Estimated completion1 September 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Paul Sabatier of Toulouse

Who can join

18 and older, any sex, with Vascular Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Groin wound infection after arterial femoral prosthetic reconstruction or percutaneous access and drug abusers are frequent and increase largely the post operative morbi-mortality. There is no perfect substitute to replace infected graft or to restaure femoral artery in septic condition moreover when all the femoral bifurcation is involved with a femoro-femoral bypass mandatory. Seeing the encouraging results of rolled pericardium patch to treat native and prosthetics aortic infections in term of patency and infection resistance, the investigators propose to evaluate the outcomes of this subsitute rolled with samples in case of femoro-femoral repair in septic condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Paul Sabatier of Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05881954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing